Warren K E

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
  2. ncbi Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group
    K Warren
    National Cancer Institute Neuro Oncology Branch, Bethesda, MD 20892 8200, USA
    Cancer Chemother Pharmacol 58:343-7. 2006
  3. ncbi A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma
    Katherine Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer 118:3607-13. 2012
  4. ncbi Genomic aberrations in pediatric diffuse intrinsic pontine gliomas
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Pediatric Neuro Oncology Section, Bldg 10 CRC, Rm 1W 5750, Bethesda, MD 20892 1104, USA
    Neuro Oncol 14:326-32. 2012
  5. ncbi A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study
    Katherine E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Neurooncol 106:643-9. 2012
  6. ncbi Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bldg 10 CRC, Rm 1 5750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 29:324-9. 2011
  7. ncbi Noninvasive assessment of pediatric brain tumors
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD, USA
    Cancer Biol Ther 8:1881-8. 2009
  8. ncbi Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E Warren
    National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 62:433-7. 2008
  9. ncbi Molecularly targeted therapy for pediatric brain tumors
    Warren K E
    National Cancer Institute, Neuro Oncology Branch, Bloch Bldg, 82, Rm 224, 9030 Old Georgetown Road, Bethesda, Maryland 20892 8200, USA
    J Neurooncol 75:335-43. 2005
  10. ncbi Current approaches to CNS tumors in infants and very young children
    Katherine E Warren
    Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Expert Rev Neurother 4:681-90. 2004

Detail Information

Publications22

  1. ncbi Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
    ....
  2. ncbi Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group
    K Warren
    National Cancer Institute Neuro Oncology Branch, Bethesda, MD 20892 8200, USA
    Cancer Chemother Pharmacol 58:343-7. 2006
    ..The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression...
  3. ncbi A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma
    Katherine Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer 118:3607-13. 2012
    ..The primary objective was to compare 2-year survival with a historic cohort that received radiation therapy alone...
  4. ncbi Genomic aberrations in pediatric diffuse intrinsic pontine gliomas
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Pediatric Neuro Oncology Section, Bldg 10 CRC, Rm 1W 5750, Bethesda, MD 20892 1104, USA
    Neuro Oncol 14:326-32. 2012
    ..This study establishes the feasibility of genomic DNA analysis from DIPG autopsy material, identifies several targets for which molecular targeted therapy exists, and suggests significant heterogeneity among patients with DIPG...
  5. ncbi A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study
    Katherine E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Neurooncol 106:643-9. 2012
    ..The combination of O6BG and TMZ did not achieve the target response rate for activity in pediatric patients with recurrent or progressive HGG and BSG...
  6. ncbi Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bldg 10 CRC, Rm 1 5750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 29:324-9. 2011
    ..A phase I trial of lenalidomide was performed in children with recurrent, refractory, or progressive primary CNS tumors to estimate the maximum-tolerated dose (MTD) and to describe the toxicity profile and pharmacokinetics...
  7. ncbi Noninvasive assessment of pediatric brain tumors
    Katherine E Warren
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD, USA
    Cancer Biol Ther 8:1881-8. 2009
    ..This article reviews these techniques and their potential application to children with brain tumors...
  8. ncbi Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E Warren
    National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 62:433-7. 2008
    ..We studied the cerebrospinal fluid (CSF) penetration of intravenous (IV) belinostat in a non-human primate model as a surrogate for blood:brain barrier penetration...
  9. ncbi Molecularly targeted therapy for pediatric brain tumors
    Warren K E
    National Cancer Institute, Neuro Oncology Branch, Bloch Bldg, 82, Rm 224, 9030 Old Georgetown Road, Bethesda, Maryland 20892 8200, USA
    J Neurooncol 75:335-43. 2005
    ..This article discusses the rationale behind several of these agents and their use in pediatric patients with brain tumors...
  10. ncbi Current approaches to CNS tumors in infants and very young children
    Katherine E Warren
    Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Expert Rev Neurother 4:681-90. 2004
    ..Achieving successful tumor control while optimizing quality of life for survivors is the major goal of recent research...
  11. ncbi Advances in the assessment of childhood brain tumors and treatment-related sequelae
    Katherine E Warren
    National Cancer Institute, Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Road, Bethesda, MD 20892, USA
    Curr Neurol Neurosci Rep 5:119-26. 2005
    ..This article reviews some of these techniques and their role in the assessment of children with brain tumors...
  12. ncbi NMR spectroscopy and pediatric brain tumors
    Katherine E Warren
    Neuro Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 8200, USA
    Oncologist 9:312-8. 2004
    ..NMRS is commonly used in the evaluation of patients with brain tumors. This article reviews the basic principles of spectroscopy and its use in evaluating pediatric patients with brain tumors...
  13. ncbi Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors
    Katherine Warren
    Neuro Oncology Branch and Pediatric Oncology Branch, National Cancer Institute, Bloch Building, 82, 9030 Old Georgetown Road, Bethesda, MD 20892 8200, USA
    Cancer Chemother Pharmacol 54:206-12. 2004
    ..To determine the pharmacokinetics of adaptively dosed carboplatin when administered in combination with the bradykinin agonist, lobradimil (RMP-7, Cereport), to pediatric patients with brain tumors...
  14. ncbi Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors
    K E Warren
    Neuro Oncology Branch, National Cancer Institute NCI and National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892 1928, USA
    J Natl Cancer Inst 93:1401-5. 2001
    ..Because software to estimate three-dimensional (3D) tumor volume from digitized MRI images is available, we compared all three methods of tumor measurement for childhood brain tumors and clinical outcome...
  15. ncbi Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 18:1020-6. 2000
    ..We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance...
  16. ncbi Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1928, USA
    Antimicrob Agents Chemother 44:1100-1. 2000
    ..Fluconazole pretreatment had no effect on doxorubicin pharmacokinetics...
  17. ncbi Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Cancer Chemother Pharmacol 48:275-82. 2001
    ..To determine the maximum tolerated dose (MTD), the incidence and severity of toxicities, and the pharmacokinetics of lobradimil administered intravenously over 10 min in combination with carboplatin in children with refractory brain tumors...
  18. ncbi Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates
    K E Warren
    Pediatric Oncology Branch, Bldg 10 Rm 13N240, 10 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 45:207-12. 2000
    ..We studied the effects of the Pgp inhibitor, cyclosporin A (CsA), on the cerebrospinal fluid (CSF) penetration of the Pgp substrate, doxorubicin, in non-human primates...
  19. ncbi Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors
    Holly J Meany
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bldg 10 CRC Rm 1 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 65:137-42. 2009
    ..Temozolomide pharmacokinetics were evaluated in children receiving concurrent O(6)-benzylguanine (O(6)BG), which enhanced the hematological toxicity of temozolomide...
  20. ncbi Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note
    Russell R Lonser
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 1414, USA
    J Neurosurg 107:190-7. 2007
    ..Patients with a variety of intrinsic brainstem and other central nervous system disorders may benefit from a similar treatment paradigm...
  21. ncbi Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy
    Emilie A Steffen-Smith
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Childs Nerv Syst 24:807-13. 2008
    ....
  22. ncbi Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas
    Robert M Hayward
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 10 CRC, Rm 1 3940, Bethesda, MD 20892, USA
    J Neurooncol 90:57-61. 2008
    ..Endpoints for clinical trials determining efficacy in this population should also include more objective measures, such as survival, and additional endpoints need to be investigated...